Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | GSK3B | P49841 | 6/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | GSK3A | P49840 | 5/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16157071 | 0.87 | MAPT (0.64) | CYP1A2CYP2C19GSK3BKDM4EALDH1A1 | |
| SCHEMBL16157136 | 0.85 | MAPT (0.70) | KDM4EHTTALDH1A1MAPK1NPC1 | |
| SCHEMBL16157178 | 0.84 | MAPT (0.54) | KDM4EHTTALDH1A1MAPK1NPC1 | |
| SCHEMBL16157161 | 0.83 | HTT (0.70) | CYP1A2CYP2C19KDM4EHTTALDH1A1 | |
| SCHEMBL16948584 | 0.79 | GSK3B (0.74) | CYP1A2CYP2C19GSK3BKDM4EGSK3A | |
| SCHEMBL5024100 | 0.77 | GSK3B (1.00) | CYP1A2CYP2C19GSK3BGSK3AHTT | |
| SCHEMBL12925122 | 0.76 | CYP1A2 (0.71) | CYP1A2CYP2C19GSK3BGSK3AHTT | |
| SCHEMBL16944469 | 0.76 | GSK3B (0.78) | CYP1A2CYP2C19GSK3BGLAGSK3A | |
| SCHEMBL17068796 | 0.75 | GLA (0.72) | CYP1A2CYP2C19GSK3BKDM4EGLA | |
| SCHEMBL17068768 | 0.75 | GLA (0.64) | CYP1A2CYP2C19GSK3BGLAGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200140425-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | MASSACHUSETTS GENERAL HOSPITAL | 2020-05-07 | — | — | US | disclosed |
| US-10301294-B2 | Compounds for the treatment of tuberculosis | The Broad Institute Inc. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20160031870-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | NIH - DEITR | 2016-02-04 | — | — | US | disclosed |
| US-20160031870-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | NIH - DEITR | 2016-02-04 | — | — | US | disclosed |
| WO-2014165090-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | THE BROAD INSTITUTE, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301294-B2 | Compounds for the treatment of tuberculosis | GOT2, G6PD, FNTB | CYP1A2 1181/4885CYP2C19 1637/4885GSK3B 2519/4885 |
| US-20200140425-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | GOT2, G6PD, FNTB | CYP1A2 1181/4885CYP2C19 1637/4885GSK3B 2519/4885 |
| US-20160031870-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | GOT2, G6PD, FNTB | CYP1A2 1181/4885CYP2C19 1637/4885GSK3B 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.